New Formulation of Tiopronin Receives FDA Approval for Treatment of Cystinuria

Officials with the FDA have approved a new enteric-coated formulation of tiopronin (Thiola EC, Retrophin) 100 mg and 300 mg tablets, for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine, resulting in the formation of recurring cystine kidney stones. According to Retrophin, these new tablets are expected to be available in July 2019…


Share this post